{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:59:13Z","timestamp":1782273553852,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.vaccine.2022.01.030","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T22:45:50Z","timestamp":1642632350000},"page":"1208-1212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines"],"prefix":"10.1016","volume":"40","author":[{"given":"Fei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canbin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruisheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinde","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.01.030_b0005","unstructured":"Organization, W.H., Draft Landscape of COVID-19 Candidate Vaccines (20201112). 2020."},{"issue":"7830","key":"10.1016\/j.vaccine.2022.01.030_b0010","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.vaccine.2022.01.030_b0015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd.2018.158","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.030_b0020","doi-asserted-by":"crossref","first-page":"e10938","DOI":"10.15252\/emmm.201910938","article-title":"Adeno-associated virus-vectored influenza vaccine elicits neutralizing and Fcgamma receptor-activating antibodies","volume":"12","author":"Demminger","year":"2020","journal-title":"EMBO Mol Med"},{"issue":"8","key":"10.1016\/j.vaccine.2022.01.030_b0025","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nm.1967","article-title":"Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys","volume":"15","author":"Johnson","year":"2009","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.01.030_b0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.virol.2006.03.049","article-title":"Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines","volume":"353","author":"Du","year":"2006","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.030_b0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.vaccine.2022.01.030_b0040","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.vaccine.2022.01.030_b0045","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis699","article-title":"Protection Against Henipavirus Infection by Use of Recombinant Adeno-Associated Virus-Vector Vaccines","volume":"207","author":"Ploquin","year":"2013","journal-title":"J Infect Dis"},{"issue":"39","key":"10.1016\/j.vaccine.2022.01.030_b0050","doi-asserted-by":"crossref","first-page":"29923","DOI":"10.1074\/jbc.R000008200","article-title":"Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters","volume":"275","author":"Park","year":"2000","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.vaccine.2022.01.030_b0055","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.vaccine.2022.01.030_b0060","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.0902724","article-title":"Cell surface heparan sulfate proteoglycans influence MHC class II-restricted antigen presentation","volume":"185","author":"L\u00e9onetti","year":"2010","journal-title":"J Immunol"},{"issue":"27","key":"10.1016\/j.vaccine.2022.01.030_b0065","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1016\/j.vaccine.2016.04.073","article-title":"Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8(+) T-cell response","volume":"34","author":"Knittel","year":"2016","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2022.01.030_b0070","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.chom.2021.08.002","article-title":"An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates","volume":"29","author":"Zabaleta","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"7830","key":"10.1016\/j.vaccine.2022.01.030_b0075","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"issue":"7853","key":"10.1016\/j.vaccine.2022.01.030_b0080","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.01.030_b0085","unstructured":"Gardner BJ, Kilpatrick AM. Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and could prevent future surges in some populations. medRxiv, 2021."},{"issue":"7871","key":"10.1016\/j.vaccine.2022.01.030_b0090","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.01.030_b0095","doi-asserted-by":"crossref","unstructured":"Tong D, et al., Single-dose AAV-based vaccine induces a high level of neutralizing antibodies and provides long-term protection against SARS-CoV-2 in rhesus macaques. bioRxiv, 2021.","DOI":"10.1093\/procel\/pwac020"},{"issue":"17","key":"10.1016\/j.vaccine.2022.01.030_b0100","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1128\/JVI.78.17.9007-9015.2004","article-title":"Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein","volume":"78","author":"Giroglou","year":"2004","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:09:57Z","timestamp":1759403397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22000548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0264410X22000548"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}